Back to Journals » Biologics: Targets and Therapy » Volume 7

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Authors Keohane C, Radia DH, Harrison CN

Received 6 September 2013

Accepted for publication 6 September 2013

Published 31 October 2013 Volume 2013:7 Pages 231—232

DOI https://doi.org/10.2147/BTT.S54093

Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198.

On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." should have been "Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)."
On page 193 in the same paragraph note that "Post-Essential Thrombocythemia Myelofibrosis: PERSIST)." should have been "Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1)."

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia

Sarma A, Mclornan DP, Harrison CN

Orphan Drugs: Research and Reviews 2017, 7:11-23

Published Date: 31 January 2017

Treatment and management of myelofibrosis in the era of JAK inhibitors

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:189-198

Published Date: 20 August 2013

Emerging treatments for essential thrombocythemia

Okoli S, Harrison C

Journal of Blood Medicine 2011, 2:151-159

Published Date: 2 December 2011

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010